吉西他滨
医学
伊布替尼
内科学
肿瘤科
安慰剂
中性粒细胞减少症
紫杉醇
化疗
胃肠病学
病理
白血病
替代医学
慢性淋巴细胞白血病
作者
Margaret A. Tempero,Do‐Youn Oh,Josep M. Tabernero,Michele Reni,Eric Van Cutsem,Andrew Eugene Hendifar,Dirk Waldschmidt,Naureen Starling,Jean‐Baptiste Bachet,Heung Moon Chang,Joan Maurel,Rocio García‐Carbonero,Sara Lonardi,Lisa M. Coussens,Lawrence H. Fong,L. Claire Tsao,George W. Cole,Danelle Frances James,Teresa Mercade Macarulla
标识
DOI:10.1016/j.annonc.2021.01.070
摘要
BACKGROUND: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC were evaluated. PATIENTS AND METHODS: ). Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS); overall response rate and safety were assessed. RESULTS: In total, 424 patients were randomized (ibrutinib arm, n = 211; placebo arm, n = 213). Baseline characteristics were balanced across arms. After a median follow-up of 25 months, there was no significant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine (median of 9.7 versus 10.8 months; P = 0.3225). PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 versus 6.0 months; P < 0.0001). Overall response rates were 29% and 42%, respectively (P = 0.0058). Patients in the ibrutinib arm had less time on treatment and received lower cumulative doses for all agents compared with the placebo arm. The most common grade ≥3 adverse events for ibrutinib versus placebo arms included neutropenia (24% versus 35%), peripheral sensory neuropathy (17% versus 8%), and anemia (16% versus 17%). Primary reasons for any treatment discontinuation were disease progression and adverse events. CONCLUSIONS: Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI